Xilio Therapeutics, Inc.
XLO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $51 | $15 | $74 | $438 |
| - Cash | $55 | $45 | $120 | $198 |
| + Debt | $8 | $11 | $20 | $21 |
| Enterprise Value | $4 | -$18 | -$27 | $260 |
| Revenue | $6 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $6 | $0 | $0 | -$1 |
| % Margin | 100% | – | – | – |
| EBITDA | -$58 | -$77 | -$87 | -$74 |
| % Margin | -914.3% | – | – | – |
| Net Income | -$58 | -$76 | -$88 | -$76 |
| % Margin | -918% | – | – | – |
| EPS Diluted | -1.09 | -2.78 | -3.19 | -2.72 |
| % Growth | 60.8% | 12.9% | -17.3% | – |
| Operating Cash Flow | -$18 | -$69 | -$76 | -$81 |
| Capital Expenditures | -$0 | -$0 | -$2 | -$1 |
| Free Cash Flow | -$18 | -$69 | -$78 | -$82 |